Tetraphase Pharmaceuticals (TTPH) Earns Overweight Rating from Piper Jaffray Companies
Tetraphase Pharmaceuticals (NASDAQ:TTPH)‘s stock had its “overweight” rating reissued by research analysts at Piper Jaffray Companies in a research report issued on Wednesday, The Fly reports. They presently have a $8.00 price objective on the biopharmaceutical company’s stock. Piper Jaffray Companies’ target price points to a potential upside of 47.33% from the company’s previous close.
TTPH has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Tetraphase Pharmaceuticals in a report on Tuesday, December 5th. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 28th. B. Riley started coverage on shares of Tetraphase Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $11.00 target price on the stock. ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Finally, BidaskClub lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $11.63.
Shares of Tetraphase Pharmaceuticals (TTPH) opened at $5.43 on Wednesday. The stock has a market cap of $281.71, a price-to-earnings ratio of -1.90 and a beta of 2.29. Tetraphase Pharmaceuticals has a twelve month low of $4.91 and a twelve month high of $9.93.
Hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC purchased a new position in Tetraphase Pharmaceuticals during the 3rd quarter valued at about $107,000. Brighton Jones LLC purchased a new position in Tetraphase Pharmaceuticals during the 3rd quarter valued at about $108,000. Voya Investment Management LLC lifted its position in Tetraphase Pharmaceuticals by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares during the period. Virtu KCG Holdings LLC purchased a new position in Tetraphase Pharmaceuticals during the 2nd quarter valued at about $147,000. Finally, Ameriprise Financial Inc. purchased a new position in Tetraphase Pharmaceuticals during the 2nd quarter valued at about $162,000. 58.28% of the stock is owned by institutional investors.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.